KEYNOTE-407 data presentation
KEYTRUDA® (pembrolizumab), in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of metastatic squamous NSCLC
Prescribing Information [External link]
Download our KEYNOTE-407 slide deck that discusses KEYTRUDA (pembrolizumab) plus carboplatin-paclitaxel/nab-paclitaxel for the first-line treatment of metastatic squamous NSCLC.
Please refer to the KEYTRUDA Summary of Product Characteristics and Risk Minimisation Materials before prescribing KEYTRUDA. Risk Minimisation Materials are available online, from your MSD representative or from MSD Medical Information (Email: medicalinformationuk@msd.com, Phone: 0208 154 8000).
Find out more information about KEYTRUDA in metastatic NSCLC:
Supporting documentation
Prescribing Information [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.
